中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2013年
3期
560-564
,共5页
郝亚荣%刘斯灵%张黎军%李芳芳
郝亞榮%劉斯靈%張黎軍%李芳芳
학아영%류사령%장려군%리방방
生物材料%生物材料循证医学%冠心病%雷帕霉素洗脱支架%安全性%有效性%主要心脏不良事件%Meta 分析
生物材料%生物材料循證醫學%冠心病%雷帕黴素洗脫支架%安全性%有效性%主要心髒不良事件%Meta 分析
생물재료%생물재료순증의학%관심병%뢰파매소세탈지가%안전성%유효성%주요심장불량사건%Meta 분석
biomaterials%evidence-based biomaterials%coronary heart diseases%rapamycin-eluting stents%safety%efficacy%major adverse cardiac events%Meta analysis
背景:药物洗脱支架治疗冠状动脉粥样硬化性心脏病能有效降低术后中远期冠状动脉再狭窄和远期心脏不良事件的发生率.目的:对比国产与进口雷帕霉素洗脱支架治疗冠状动脉粥样硬化性心脏病的安全性和有效性.方法:按照循证医学要求全面检索国内外近5年来有关国产和进口雷帕霉素洗脱支架治疗冠状动脉粥样硬化性心脏病的随机对照或临床对照试验,对符合纳入标准的文献进行 Meta 分析.结果与结论:共纳入16篇临床对照试验,其中2603例使用国产雷帕霉素洗脱支架,2646例使用进口雷帕霉素洗脱支架.国产雷帕霉素洗脱支架组与进口雷帕霉素洗脱支架组主要心脏不良事件、靶血管血运重建、心源性死亡、心肌梗死、支架内血栓发生率差异均无显著性意义.显示从目前临床研究看,国产雷帕霉素洗脱支架在安全性和有效性方面不亚于进口雷帕霉素洗脱支架.
揹景:藥物洗脫支架治療冠狀動脈粥樣硬化性心髒病能有效降低術後中遠期冠狀動脈再狹窄和遠期心髒不良事件的髮生率.目的:對比國產與進口雷帕黴素洗脫支架治療冠狀動脈粥樣硬化性心髒病的安全性和有效性.方法:按照循證醫學要求全麵檢索國內外近5年來有關國產和進口雷帕黴素洗脫支架治療冠狀動脈粥樣硬化性心髒病的隨機對照或臨床對照試驗,對符閤納入標準的文獻進行 Meta 分析.結果與結論:共納入16篇臨床對照試驗,其中2603例使用國產雷帕黴素洗脫支架,2646例使用進口雷帕黴素洗脫支架.國產雷帕黴素洗脫支架組與進口雷帕黴素洗脫支架組主要心髒不良事件、靶血管血運重建、心源性死亡、心肌梗死、支架內血栓髮生率差異均無顯著性意義.顯示從目前臨床研究看,國產雷帕黴素洗脫支架在安全性和有效性方麵不亞于進口雷帕黴素洗脫支架.
배경:약물세탈지가치료관상동맥죽양경화성심장병능유효강저술후중원기관상동맥재협착화원기심장불량사건적발생솔.목적:대비국산여진구뢰파매소세탈지가치료관상동맥죽양경화성심장병적안전성화유효성.방법:안조순증의학요구전면검색국내외근5년래유관국산화진구뢰파매소세탈지가치료관상동맥죽양경화성심장병적수궤대조혹림상대조시험,대부합납입표준적문헌진행 Meta 분석.결과여결론:공납입16편림상대조시험,기중2603례사용국산뢰파매소세탈지가,2646례사용진구뢰파매소세탈지가.국산뢰파매소세탈지가조여진구뢰파매소세탈지가조주요심장불량사건、파혈관혈운중건、심원성사망、심기경사、지가내혈전발생솔차이균무현저성의의.현시종목전림상연구간,국산뢰파매소세탈지가재안전성화유효성방면불아우진구뢰파매소세탈지가.
@@@@BACKGROUND: The use of drug-eluting stents in the treatment of coronary atherosclerotic heart disease is effective in decreasing restenosis after percutaneous transluminal coronary artery angioplasty and major adverse cardiac events in medium- and long-term. OBJECTIVE: To assess the safety and efficacy of domestic and imported rapamycin-eluting stents for the treatment of coronary heart disease. METHODS: The literatures about domestic and imported rapamycin-eluting stents in the treatment of coronary heart disease are comprehensively searched in accordance with the demands of the evidence-based medicine in the last 5 years. Meta-analysis was conducted on the literatures enrol ed. RESULTS AND CONCLUSION: Total y 16 control ed clinical trials were enrol ed, including 2 603 cases undergoing domestic rapamycin-eluting stents and 2 646 cases undergoing imported rapamycin-eluting stents. Meta-analysis results suggested no statistical difference in major adverse cardiac events, target vessel revascularization, cardiac death, myocardial infarction, and stent thrombosis incidence between the domestic and imported rapamycin-eluting stents. It is indicated that from the present clinical trials, domestic rapamycin-eluting stents are not secondary to imported rapamycin-eluting stents in safety and efficacy.